Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

PURPOSE: Patients who do not complete one cycle of therapy on Phase I trials for reasons other than dose limiting toxicity (DLT) are considered inevaluable for toxicity and must be replaced. METHODS: Individual records from patients enrolled to NCI-sponsored Phase I trials activated between 2000 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyman, David M., Eaton, Anne A., Gounder, Mrinal M., Pamer, Erika G., Pettiford, Jasmine, Carvajal, Richard D., Ivy, S. Percy, Iasonos, Alexia, Spriggs, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662493/
https://www.ncbi.nlm.nih.gov/pubmed/25682870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662493/
https://www.ncbi.nlm.nih.gov/pubmed/25682870

Ejemplares similares